17th May 2018 10:55
LONDON (Alliance News) - Inhaled product design and development firm Vectura Group PLC said on Thursday based on its trading performance for the year-to-date revenue is currently in line with management expectations.
Revenue growth is being driven by some of Vectura's key inhaled products such as Flutiform and Ultibro, the company said.
"We have made a good start to the year and see the performance from our in-market business tracking as expected. We are making significant progress with our pipeline with a broad series of news flow anticipated for the rest of 2018, including our novel partnered projects, generic projects, late stage nebulised studies and further Vectura enhanced programmes," said Chief Executive James Ward-Lilley.
Shares in Vectura Group were up 0.2% on Thursday at 85.96 pence each.
Related Shares:
VEC.L